Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
10.1097/CM9.0000000000003355
- VernacularTitle:Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
- Author:
Da ZHOU
1
;
Jiangao FAN
Author Information
1. Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, China
- Keywords:
Metabolic dysfunction-associated steatotic liver disease;
Metabolic dysfunction-associated steatohepatitis;
Nonalcoholic steatohepatitis;
Non-alcoholic f
- From:
Chinese Medical Journal
2024;137(22):2687-2696
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic dysfunction-associated steatotic liver disease (MASLD), also called non-alcoholic fatty liver disease, is the most epidemic chronic liver disease worldwide. Metabolic dysfunction-associated steatohepatitis (MASH) is the critical stage of MASLD, and early diagnosis and treatment of MASH are crucial for reducing the incidence of intrahepatic and extrahepatic complications. So far, pharmacotherapeutics for the treatment of MASH are still a major challenge, because of the complexity of the pathogenesis and heterogeneity of MASH. Many agents under investigation have shown impressive therapeutic effects by targeting different key pathways, including the attenuation of steatohepatitis or fibrosis or both. It is notable that thyroid hormone receptor-β agonist, resmetirom has become the first officially approved drug for treating MASH with fibrosis. Other agents such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 analogs, and fibroblast growth factor 21 analogs are awaiting approval. This review focuses on the current status of drug therapy for MASH and summarizes the latest results of new medications that have completed phase 2 or 3 clinical trials, and presents the future directions and difficulties of new drug research for MASH.
